STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • November 25th, 2020 • 4D Pharma PLC • Texas
Contract Type FiledNovember 25th, 2020 Company JurisdictionThis Strategic Collaboration Agreement ("Agreement"), effective as of the 10th day of November, 2017 ("Effective Date"), is entered into by and between The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030, USA ("MD Anderson"), a member institution of The University of Texas System ("System") and 4D pharma plc with a place of business located at 9 Bond Court Leeds LS1 2JZ, United Kingdom ("Company") (MD Anderson and Company each a "Party" and collectively the "Parties").
RESEARCH COLLABORATION AND OPTION TO LICENSE AGREEMENT by and between 4D PHARMA PLC and MERCK SHARP & DOHME CORP.Research Collaboration and Option to License Agreement • November 25th, 2020 • 4D Pharma PLC • England and Wales
Contract Type FiledNovember 25th, 2020 Company JurisdictionThis Agreement (this “Agreement”) is effective as of October 7, 2019, (the “Effective Date”) and is entered into by and between 4D Pharma plc, having an address of 9 Bond Court, Leeds LS l 2JZ, United Kingdom (organized and existing under the laws of England and Wales (“Company”) and MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey (“MSD”).
VOTING AND SUPPORT AGREEMENTVoting and Support Agreement • November 25th, 2020 • 4D Pharma PLC • Delaware
Contract Type FiledNovember 25th, 2020 Company Jurisdiction
AGREEMENT AND PLAN OF MERGER by and among 4D PHARMA PLC, DOLPHIN MERGER SUB LIMITED and LONGEVITY ACQUISITION CORPORATION OCTOBER 21, 2020Agreement and Plan of Merger • November 25th, 2020 • 4D Pharma PLC • Delaware
Contract Type FiledNovember 25th, 2020 Company JurisdictionTHIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of October 21, 2020 (the “date hereof”), is made by and among 4D pharma plc, a public limited company incorporated under the laws of England and Wales (“Parent”), Dolphin Merger Sub Limited, a British Virgin Islands company limited by shares (“Merger Sub”), and Longevity Acquisition Corporation, a British Virgin Islands company limited by shares (the “Company”). The Company, Parent and Merger Sub will each be referred to herein from time to time as a “Party” and, collectively, as the “Parties.” Capitalized terms used and not otherwise defined herein have the meanings set forth in ARTICLE X below.